<DOC>
	<DOCNO>NCT00009828</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness paclitaxel combine fluorouracil-uracil leucovorin treat patient solid tumor .</brief_summary>
	<brief_title>Paclitaxel Combined With Fluorouracil-Uracil Leucovorin Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose weekly paclitaxel combine fluorouracil-uracil leucovorin calcium patient solid tumor . II . Determine side effect toxicity regimen patient . OUTLINE : This dose escalation study paclitaxel . Patients receive paclitaxel IV day 1 , 8 , 15 . Patients also receive oral fluorouracil-uracil leucovorin calcium twice daily day 2-6 , 9-13 , 16-20 . Treatment repeat every 4 week 6 course absence progressive disease unacceptable toxicity . Cohorts 3-6 patient receive escalate dos paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 6 patient experience dose-limiting toxicity . Patients follow 2 month survival . PROJECTED ACCRUAL : Approximately 25-30 patient accrue study .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor curative effective therapy available No symptomatic uncontrolled brain leptomeningeal metastasis Irradiated brain metastasis allow neurological status stable 4 week radiotherapy PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm3 Absolute neutrophil count least 1,500/mm3 Hepatic : SGOT great 1.5 time upper limit normal ( ULN ) Bilirubin great ULN No acute hepatitis Renal : Not specify Cardiovascular : No unstable cardiac disease require treatment No cardiac arrhythmia No new onset crescendo rest angina Stable exertional angina allow Neurological : No symptomatic peripheral neuropathy great grade 1 No significant neurological psychiatric disorder include psychotic disorder , dementia , seizures Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 week follow study No serious illness medical condition No active infection , include septicemia No severe gastrointestinal bleeding No hypersensitivity leucovorin calcium fluorouraciluracil No psychological , familial , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy No concurrent colonystimulating growth factor within 24 hour fluorouraciluracil Chemotherapy : No 1 prior regimen chemotherapy Prior taxanes fluorouracil allow At least 3 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy : At least 3 week since prior hormonal therapy recover No concurrent anticancer hormonal agent Radiotherapy : At least 3 week since prior radiotherapy recover Concurrent radiotherapy allow palliation painful bone metastasis , pathologic fracture know lytic disease , brain lesion Surgery : Not specify Other : At least 3 week since prior investigational drug No concurrent antiarrhythmic medication No concurrent investigational therapy No concurrent halogenated antiviral agent ( e.g. , lodenosine , fialuridine , clevudine , emtricitabine , sorivudine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>